Novo Nordisk , the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

The Danish pharmaceutical company behind obesity drug Wegovy, Novo Nordisk, plans to invest US$1.09bn in expanding its ...

In the sleepy suburb of Bagsværd, a 25-minute train ride from Denmark’s capital of Copenhagen, weight-loss drugmaker Novo Nordisk is everywhere. Street after street is filled with the company ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 ...

LONDON/COPENHAGEN (Reuters) - Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday.

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). This Scandinavian economic behemoth ...

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and ...

Novo Nordisk A/S Bagsværd, Denmark, 3 April 2025 – Novo Nordisk today announced the following changes in Executive Management. After a distinguished career of 28 years with Novo Nordisk, hereof ...

Shares of Novo Nordisk ended higher on Monday and extended gains in after-hours trading, while "Big Pharma" rival Eli Lilly ...

Well before market open that morning, Morgan Stanley's Thibault Boutherin knocked his Novo Nordisk price target down to 600 Danish kroner ($86.67) per share; previously, this number was 700 kroner ...

For Novo Nordisk A/S investors (NVO), things couldn't have gotten to a worse start this week. Just when the market was preparing for a bottom, as NVO has been consolidating constructively over the ...